PubMed Health⌕ Search

Biomedical subjects

A A Smorodintsev

Publications and source records attributed to A A Smorodintsev.

At least 19 recordsLinked to original sources
PubMed1992

[Live enteroviral vaccines for the emergency nonspecific prevention of mass respiratory diseases during fall-winter epidemics of influenza and acute respiratory diseases].

The results of the 3-year controlled trials of a new method of nonspecific urgent prophylaxis of influenza and acute respiratory diseases (ADR) by immunization of healthy adults with standard live enterovirus oral vaccines, introduced in 2-3 administrations at intervals of 7-10 days, at the initial stages of autumn and winter epidemics are presented. Observations, carried out in three republics, covered more than 150,000 persons immunized with enterovirus interferonogenic vaccines. A considerable decrease in morbidity rate among the vaccinees was achieved (on the average, by 3.2 times) in comparison to that among nonimmunized subjects. The method of nonspecific prophylaxis with live enterovirus interferonogenic vaccines is recommended during outbreaks of diseases induced simultaneously by several causative agents of influenza and ARD, as well as by pathogenic enterovirus strains.

Acute Disease↗
PubMed1990

An experience with application of human leucocyte interferon for cervical cancer treatment.

Interferon was injected intracervically as the first stage of combination treatment in 125 cases of histologically verified squamous Ca in situ and invasive cervical carcinoma. Colpomicroscopic, cytological and histological examination was carried out before and after treatment. The pronounced effect of interferon as an antitumor agent was established. Post-treatment histological examination failed to detect any tumor cells in 36 out of 125 patients (28.8%). Widening the scope of indications for preservative operations in patients with preinvasive and microinvasive cervical carcinoma after preliminary interferon therapy was suggested.

Carcinoma in Situ↗
PubMed1988

[Biosynthesis and main biological properties of human gamma interferon].

Conditions for and regularities of gamma-interferon production were elucidated. High interferon inducing activity of the known inductors such as concanavalin A, phytohemagglutinin and lentil lectin was asserted. It was shown that aqueous and alcoholic extracts of legumes seeds were also able to induce interferon synthesis in cultures of human peripheral blood leukocytes. By physicochemical properties such as stability to acids and liability to heating and by antigenic properties, interferon produced under such conditions was of type 2 (gamma). The maximum yield of interferon was observed in stationary and roller leukocyte cultures at a density of 2.10(6)-4.10(6) cells/ml on commercial rich media (IMDM and Eagle medium). Dynamics of gamma-interferon biosynthesis was determined. The peak of interferon production after the leukocyte induction with plant lectins was recorded in 72-96 hours.

Cells, Cultured↗
PubMed1987

[Effect of regulator cells induced by the influenza virus in adoptive transfer].

The protective effect of humoral and cellular immunity factors on experimental mouse influenza infection was studied in combination with a simultaneous analysis of the functional activity in the regulatory lymphocytes of donor mice. The efficacy of adoptive defense of recipient mice, that is the intensity of immune reactions in their organisms, was found to depend on the concrete functional state of donor mouse transferring cells. The exact time of activation of T-helper cells open certain prospects for the concrete pathogenetically grounded drug therapy.

Animals↗
PubMed1986

Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial.

Live cold-adapted recombinant bivalent vaccine of influenza type A was studied in a controlled field trial in 1982-1983 among nearly 30,000 children 3-15 years old. The bivalent vaccine consisted of recombinants 47/25/1 (H1N1) and 47/7/2 (H3N2) of wild-type viruses A/Brazil/11/78 (H1N1) and A/Bangkok/1/79 (H3N2) with cold-adapted donor A/Leningrad/134/47/57 (H2N2). The recombinants which received mutant nonglycoprotein genes from cold-adapted donor did not suppress each other after simultaneous inoculation of children and stimulated antibody response to both strains. The bivalent vaccine was completely attenuated for children. It caused less than 1% transient febrile reactions during five days after the first vaccination, including double seronegative individuals with low antibody titres to both vaccinal strains. The cold-adapted bivalent vaccine tested proved to be safe for children according to the analysis of morbidity studies among vaccines and a control group performed during the five days and the following six months after the first immunization. There is a similar distribution of non-influenza illnesses and a statistically significant decrease in influenza-like diseases among vaccines compared to the control group. In the four months after the immunization programme was completed, epidemics of influenza A H1N1 and H3N2 occurred. The incidence of influenza-like diseases was approximately 50% less in the vaccinated than in the control groups. This is the first evidence of safety and protective efficacy of recombinant live influenza vaccine for children 3-15 years of age.

Adolescent↗
PubMed1986

[Experience with clinical use of human leukocyte interferon in cancer of the cervix uteri].

Interferon was injected intracervically as the first stage of combination treatment in 110 cases of histologically-verified Ca in situ and invasive cervical carcinoma. Colpomicroscopic, cytologic and histologic examination was carried before and after treatment. Posttreatment histologic examination failed to detect any tumor cells in 31 patients (28.1%). Pronounced antitumor action of interferon was established.

Carcinoma↗